Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis (Nasdaq: CRIS) priced a public offering with certain new and existing healthcare-focused institutional investors for 3,733,334 shares of common stock (or pre-funded warrants in lieu thereof) plus accompanying warrants to purchase up to 3,733,334 shares at a combined price of $1.50 per share and warrant, or $1.49 per pre-funded warrant and warrant.
The common warrants have a $1.75 exercise price, are exercisable immediately and expire five years from issuance; pre-funded warrants have a $0.01 exercise price and are exercisable immediately until fully exercised. Curis expects gross proceeds of about $5.6 million, before fees and expenses, to fund research and development, working capital and general corporate purposes. Closing is expected around August 14, 2026, subject to customary conditions.
Curis (NASDAQ: CRIS) reported an enrollment milestone in its TakeAim CLL study evaluating emavusertib, an oral IRAK4/FLT3 inhibitor, in Chronic Lymphocytic Leukemia. The company has now dosed the first five patients, after previously opening 11 sites and consenting 10 patients.
Curis reaffirmed its expectation to present initial data from 5–10 CLL patients in December 2026. The study combines emavusertib with the BTK inhibitor zanubrutinib to achieve dual NF-kB pathway blockade (BCR and TLR), aiming for deeper responses, complete remissions and undetectable minimal residual disease. According to Curis, the regimen appears well tolerated so far, with possible early signs of deepening responses, although patient numbers remain small.
Curis (NASDAQ: CRIS) reported updated clinical data for emavusertib (CA-4948) in Primary CNS Lymphoma (PCNSL) from the TakeAim Lymphoma study and updated enrollment guidance for the TakeAim CLL Phase 2 study, and will host a webcast on July 22, 2026 at 8:30 a.m. ET.
In PCNSL as of July 1, 2026, BTK inhibitor (BTKi)-naïve patients showed a 100% objective response rate (ORR) in 5 of 5 evaluable patients and 86% ORR in all 7 patients, compared with 71% (5 of 7) in prior data as of May 1, 2025. BTKi-experienced patients demonstrated a 33% ORR in 10 of 30 evaluable patients and 26% ORR in all 39 patients, versus 27% (7 of 26) previously.
For TakeAim CLL, Curis disclosed that 10 patients have now been consented, with the first five expected to be dosed by the end of July 2026. The company increased its year-end 2026 data guidance from 5 patients to 5–10 patients.
Curis (NASDAQ: CRIS) reported an enrollment milestone in its TakeAim CLL study of emavusertib combined with a BTK inhibitor.
The company has consented the first six CLL patients, has 11 clinical sites open, reaffirmed guidance to dose five patients by end of July 2026, and expects initial CLL data in December 2026.
Curis (NASDAQ: CRIS) reported operational and corporate updates. Eleven clinical sites are now open for enrollment in the Phase 2 TakeAim CLL study of emavusertib with zanubrutinib. Curis reaffirmed guidance to dose the first five patients by end of July 2026, with data expected December 2026. Stockholders approved a reverse stock split at a 1-for-5 to 1-for-25 ratio to support regaining Nasdaq $1.00 bid price compliance, with final terms to be set by the board.
Curis (NASDAQ:CRIS) reported first quarter 2026 results and a business update focused on emavusertib (CA-4948).
- Q1 2026 net loss was $24.2M with no revenue after the Erivedge royalty sale.
- R&D expenses fell to $6.4M, while G&A rose to $5.1M.
- Other expense increased to $12.7M, mainly from warrant liability changes tied to the January 2026 PIPE financing.
- Cash and equivalents totaled $15.0M with about 40M shares outstanding.
- The January 2026 PIPE provides up to $80.8M gross proceeds via initial funding and three warrant series at $0.75 per share.
- Curis expects its cash plus potential $20.2M Series B warrant proceeds to fund operations into the second half of 2027.
- Key trials include Phase 1/2 TakeAim Lymphoma in PCNSL and Phase 2 TakeAim CLL with BTK inhibitors, plus early solid tumor data showing manageable toxicity and encouraging preliminary signals.
Curis (NASDAQ: CRIS) will report first quarter 2026 financial and operating results on May 12, 2026 at 4:00 p.m. ET and will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET.
Dial-in numbers and a live audio webcast are available; a replay will be posted at www.curis.com.
Curis (NASDAQ: CRIS) reported Q4 2025 results and a business update on March 19, 2026. Key highlights include Q4 net income of $19.4M and FY 2025 net loss of $7.6M, a $27.2M non-cash gain from extinguishing a royalty liability, and a PIPE financing structure providing up to $80.8M in potential proceeds.
Clinical updates: encouraging emavusertib combo signals in PCNSL (100% ORR in 5 BTKi-naïve patients; 37% ORR in BTKi-experienced) and AML MRD conversions (5 of 8). Emavusertib holds orphan designation in PCNSL from FDA and EMA. Cash was $5.1M with guidance to fund operations into H2 2027 assuming expected warrant proceeds.
Curis (NASDAQ: CRIS) will report fourth quarter 2025 financial and operating results on Thursday, March 19, 2026 at 4:00 p.m. ET.
Management will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET; dial-in numbers and a live audio webcast will be available via the company website, with a replay posted at www.curis.com.
Curis (NASDAQ: CRIS) announced the closing of a private placement (PIPE) raising up to $80.8 million in gross proceeds, with initial gross proceeds of approximately $20.2 million to the company, before placement agent fees and offering expenses. The PIPE was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, and The Red Hook Fund, and included participation from other new and existing institutional investors as well as members of Curis' management team and board. Laidlaw & Company (UK) Ltd. acted as sole placement agent.